publication . Article . 2018

Covid-19 in a patient with ANCA-associated systemic vasculitis, receiving anti-B cell therapy (rituximab)

T. V. Beketova; L. M. Blank; A. Lila;
Open Access Russian
  • Published: 01 Jun 2018 Journal: Научно-практическая ревматология, volume 58, issue 4, pages 456-462 (issn: 1995-4484, eissn: 1995-4492, Copyright policy)
  • Publisher: IMA-PRESS LLC
Abstract
Despite numerous publications on COVID-19, at present, conceptual thinking of the problem is only at a nascence stage. Treatment of patients with ANCA-associated systemic vasculitis (AAV) during the COVID-19 pandemic is one of the relevant issues. Management of COVID-19 in AAV patients undergoing anti-B cell therapy with rituximab (RTM) requires comprehensive reasoning. This paper presents a case report about COVID-19 in a 59-year-old female with AAV in remission, who was previously treated with RTM. COVID-19 was diagnosed one month after the last RTM administration; there were moderate bilateral pneumonia, fever, and extrapulmonary manifestations, including les...
Persistent Identifiers
Subjects
free text keywords: covid-19, rituximab, b cells, anca, vasculitis, Diseases of the musculoskeletal system, RC925-935, granulomatosis with polyangiitis, B cell, medicine.anatomical_structure, medicine, Granulomatosis with polyangiitis, medicine.disease, business.industry, business, Rituximab, medicine.drug, Vasculitis, Cell therapy, Respiratory failure, Pandemic, Internal medicine, medicine.medical_specialty, Systemic vasculitis, lcsh:Diseases of the musculoskeletal system, lcsh:RC925-935
Any information missing or wrong?Report an Issue